Nordic Capital-backed ADVANZ PHARMA Corp, a UK-headquartered pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, is to acquire the majority of Intercept Pharmaceuticals’ subsidiaries and operations in Europe, Canada, and all other markets outside of the US.
This includes the ex-US rights to commercialise Ocaliva (obeticholic acid) for primary biliary cholangitis (PBC), a progressive autoimmune disease that damages the bile ducts in the liver. Intercept is a US-based biopharmaceutical company focused on the development and commercialisation of novel therapeutics to treat progressive non-viral liver diseases.
The majority of Intercept employees outside of the US will be transferring to ADVANZ PHARMA.
